These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Botulinum toxin type A and a rehabilitation program in the treatment of Pisa syndrome in Parkinson's disease. Santamato A; Ranieri M; Panza F; Zoccolella S; Frisardi V; Solfrizzi V; Amoruso MT; Amoruso L; Fiore P J Neurol; 2010 Jan; 257(1):139-41. PubMed ID: 19763384 [No Abstract] [Full Text] [Related]
7. Botulinum Neurotoxin Therapy for Lingual Dystonia Using an Individualized Injection Method Based on Clinical Features. Yoshida K Toxins (Basel); 2019 Jan; 11(1):. PubMed ID: 30658420 [TBL] [Abstract][Full Text] [Related]
9. Blepharospasm as a Manifestation of Peak of Dose Dyskinesia in Parkinson Disease. Ramírez-Gómez CC; Zúñiga-Ramírez C; Contartese ML; Montilla V; Gramajo J; Micheli F Clin Neuropharmacol; 2019; 42(1):14-16. PubMed ID: 30649026 [TBL] [Abstract][Full Text] [Related]
10. Sudden appearance of invalidating dyskinesia-dystonia and off fluctuations after the introduction of levodopa in two dopaminomimetic drug naive patients with stage IV Parkinson's disease. Onofrj M; Paci C; Thomas A J Neurol Neurosurg Psychiatry; 1998 Oct; 65(4):605-6. PubMed ID: 9771801 [No Abstract] [Full Text] [Related]
11. A family with hereditary juvenile dystonia-parkinsonism. Ishikawa A; Miyatake T Mov Disord; 1995 Jul; 10(4):482-8. PubMed ID: 7565830 [TBL] [Abstract][Full Text] [Related]
12. Ropinirole as compared with levodopa in Parkinson's disease. Hiner BC; Earnhart M N Engl J Med; 2000 Sep; 343(12):884; author reply 885. PubMed ID: 11001684 [No Abstract] [Full Text] [Related]
13. Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson's disease. LeWitt PA Mov Disord; 1998 Jul; 13(4):731-4. PubMed ID: 9686783 [TBL] [Abstract][Full Text] [Related]
14. Botulinum toxin in the treatment of lingual movement disorders. Kasravi N; Jog MS Mov Disord; 2009 Nov; 24(15):2199-202. PubMed ID: 19795478 [TBL] [Abstract][Full Text] [Related]
15. The Movement Disorder Society--14th International Congress of Parkinson's Disease and Movement Disorders. Grosset D; Grosset A IDrugs; 2010 Aug; 13(8):539-42. PubMed ID: 20721824 [TBL] [Abstract][Full Text] [Related]
16. Long-term L-DOPA therapy: challenges to our understanding and for the care of people with Parkinson's disease. Nutt JG Exp Neurol; 2003 Nov; 184(1):9-13. PubMed ID: 14637071 [No Abstract] [Full Text] [Related]
17. Thirty five years of experience in the treatment of Parkinson's disease with levodopa and associations. Chouza C; Buzó R; Scaramelli A; Romero S; de Medina O; Aljanati R; Dieguez E; Lisanti N; Gomensoro J J Neural Transm Suppl; 2006; (70):427-31. PubMed ID: 17017563 [No Abstract] [Full Text] [Related]
18. Profile of levodopa-induced dyskinesia in patients of Parkinson's disease: a record based study. Choudhury S; Pradhan R; Paul P; Das M; Gupta A; Ghosh P; Chatterjee S Neurol Res; 2014 Sep; 36(9):841-6. PubMed ID: 24601722 [TBL] [Abstract][Full Text] [Related]
19. Levodopa-associated hemifacial dystonia. Mark MH; Sage JI Mov Disord; 1991; 6(4):383. PubMed ID: 1758464 [No Abstract] [Full Text] [Related]
20. Current controversies: levodopa in the treatment of Parkinson's disease. Sharma JC; Vassallo M; Ross IN Mov Disord; 2005 May; 20(5):642-3; author reply 643-4. PubMed ID: 15732129 [No Abstract] [Full Text] [Related] [Next] [New Search]